Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

Medicus Pharma completes patient enrolment for basal cell carcinoma trial

Interim results have shown over 60% clinical clearance in patients treated with SkinJect

Headshot of Sarah Theobald with text reading 'Healthcare communications trends in 2026'

What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends

By Sarah Theobald

Amiculum

- PMLiVE

FDA approves first gene therapy for Wiskott-Aldrich syndrome

Symptoms of the rare disease include bleeding, eczema and frequent infections

- PMLiVE

Researchers at University of Geneva develop test platform for cancer treatments

The new platform could speed up testing while reducing the need for animal models

Healthcare setting

Clinical research in 2026: The trends shaping tomorrow

Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.

Cuttsy + Cuttsy

- PMLiVE

Lack of education causes patients to stop vital treatments, survey finds

Over three quarters of healthcare professionals call for co-created patient materials to drive engagement and trust, ultimately helping more patients benefit from prescribed treatments. Nearly 80% of healthcare professionals identify...

Healthinote (by Cognitant)

- PMLiVE

Lilly and Indiana University collaborate to expand clinical trial access

The five-year agreement includes a focus on R&D for Alzheimer’s disease

- PMLiVE

CGT Catapult establishes industry safety consortium for cell therapies

A universal safety test for CGTs could reduce both costs and wait times for treatment

- PMLiVE

The trust crisis: how pharma must evolve to engage Gen Z HCPs

Trust isn’t a campaign outcome; it’s the product of behaviour, language and consistency

- PMLiVE

Lilly announces plans for $6bn US manufacture facility

The site is the third of four new US sites that Lilly has announced

- PMLiVE

Kymera reports positive results in clinical trial for atopic dermatitis

KT-621 could become a first-in-class, once-a-day oral treatment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links